The enGene Holdings Inc. (ENGN) share price is expected to increase by 244.26% over the next year. This is based on calculating the average 12-month share price estimate provided by 0 stock analysts who have covered ENGN. Price targets range from $16 at the low end to $40 at the high end. The current analyst consensus for ENGN is a sell. Please note analyst price targets are not guaranteed and could be missed completely.
About 0 Wall Street analysts have assignedENGN 0 buy ratings, 0 hold ratings, and 0 sell ratings. This means that analysts expect enGene Holdings Inc. to sell. Keep in mind that these ratings are typically refreshed every quarter, underscoring the importance of conducting your own research on ENGN. Don't forget to include both technical and fundamental analysis, as well as staying informed on news that could influence these ratings, in your due diligence.
These are the latest 20 analyst ratings of ENGN.
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
---|---|---|---|---|
Leland Gershell Oppenheimer | Outperform | $30 | Reiterates | Sep 24, 2024 |
Jeffrey Hung Morgan Stanley | Overweight | $40 | Maintains | Sep 11, 2024 |
Leland Gershell Oppenheimer | Outperform | $30 | Initiates | Aug 28, 2024 |
Yanan Zhu Wells Fargo | Overweight | $30 | Initiates | Apr 22, 2024 |
Manuel Navas Guggenheim | Buy | $34 | Initiates | Apr 15, 2024 |
Colin Bristow UBS | Buy | $37 | Initiates | Mar 28, 2024 |
Jeffrey Hung Morgan Stanley | Overweight | $40 | Initiates | Mar 8, 2024 |
Mani Foroohar Leerink Partners | Outperform | $31 | Initiates | Feb 20, 2024 |
When did it IPO
2023
Staff Count
31
Country
Canada
Sector/Industry
Healthcare/Biotechnology
CEO
Mr. Jason D. Hanson Esq., J.D.
Market Cap
$376.7M
In 2023, ENGN generated $0 in revenue, which was a increase of 0.00% from the previous year. This can be seen as a signal that ENGN's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Summary - enGene Holdings Inc. is conducting a pivotal study on its lead product, detalimogene voraplasmid, for bladder cancer treatment and has agreed to sell 6,758,311 shares.
Why It Matters - enGene's pivotal study and stock sale indicate progress in its clinical development and potential for funding. This could affect its market valuation and investor sentiment.
Summary - enGene Holdings Inc. appointed Joan Connolly as Chief Executive Officer. The company is conducting a pivotal study on its lead product for high-risk bladder cancer.
Why It Matters - The appointment of a new Chief Executive Officer can signal strategic shifts and leadership changes that may impact enGene's direction and stock performance, crucial for investors tracking the company's progress.
Summary - enGene Holdings Inc. announced the grant of an inducement equity award as it continues a pivotal study for its lead product, detalimogene voraplasmid, targeting high-risk NMIBC patients.
Why It Matters - enGene's pivotal study results could impact stock performance and market perception, especially in biotech, as success in treating high-risk cancer may lead to increased demand and valuation.
Summary - enGene Holdings Inc. reported the grant of inducement equity awards as it continues a pivotal study on its lead product, detalimogene voraplasmid, for high-risk bladder cancer.
Why It Matters - The grant of inducement equity awards suggests management's confidence in the company's prospects, potentially influencing investor sentiment and stock performance.
Summary - enGene Holdings Inc. announced preliminary data from its pivotal study on detalimogene voraplasmid for high-risk, BCG-unresponsive non-muscle invasive bladder cancer.
Why It Matters - Preliminary data on enGene's lead product for bladder cancer may signal progress in a pivotal study, potentially influencing stock performance and investor sentiment in biotech.
Summary - enGene Holdings Inc. reported its Q3 financial results and is conducting a pivotal study on its lead product, detalimogene voraplasmid, for high-risk non-muscle invasive bladder cancer.
Why It Matters - enGene's pivotal study for a cancer treatment positions it for potential market success, impacting stock performance and investor sentiment based on clinical outcomes and financial health.